The aim of the project is to establish a two-component treatment scheme for tumor therapy: On the one hand, the cell cycle is stopped by a tumor suppressor pulse activation. This protects normal cells while leaving tumor suppressor-mutant cancer cells vulnerable to DNA-damaging chemotherapeutic agents. As DNA-damaging chemotherapeutic agents, the team wants to use a bioorthogonal reaction, a highly specific process that does not disrupt normal biological processes, between an engineered nucleoside, a DNA building block lacking phosphate groups, and a DNA intercalator that binds within the double helix. The project team thus presents a promising treatment regimen that only eliminates cells with mutated tumor suppressor while sparing wild-type cells of the tumor suppressor. In the current application the team wants to establish a systemic therapy for mouse tumors using the two-component treatment regimen.
Here you an find further information.